These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 10977030)
21. Smoking enhances absorption of insulin but reduces glucodynamic effects in individuals using the Lilly-Dura inhaled insulin system. Wise S; Chien J; Yeo K; Richardson C Diabet Med; 2006 May; 23(5):510-5. PubMed ID: 16681559 [TBL] [Abstract][Full Text] [Related]
22. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Becker RH; Sha S; Frick AD; Fountaine RJ Diabetes Care; 2006 Feb; 29(2):277-82. PubMed ID: 16443873 [TBL] [Abstract][Full Text] [Related]
23. Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device. Forst T; Hohberg C; Schöndorf T; Borchert M; Forst S; Roth W; Dehos B; Pfützner A Diabetes Technol Ther; 2009 Feb; 11(2):87-92. PubMed ID: 19848574 [TBL] [Abstract][Full Text] [Related]
24. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. Heise T; Bott S; Tusek C; Stephan JA; Kawabata T; Finco-Kent D; Liu C; Krasner A Diabetes Care; 2005 Sep; 28(9):2161-9. PubMed ID: 16123484 [TBL] [Abstract][Full Text] [Related]
25. AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. Wolzt M; de la Peña A; Berclaz PY; Tibaldi FS; Gates JR; Muchmore DB Diabetes Care; 2008 Apr; 31(4):735-40. PubMed ID: 18192544 [TBL] [Abstract][Full Text] [Related]
26. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Rave KM; Nosek L; de la Peña A; Seger M; Ernest CS; Heinemann L; Batycky RP; Muchmore DB Diabetes Care; 2005 Oct; 28(10):2400-5. PubMed ID: 16186270 [TBL] [Abstract][Full Text] [Related]
27. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Brunner GA; Balent B; Ellmerer M; Schaupp L; Siebenhofer A; Jendle JH; Okikawa J; Pieber TR Diabetologia; 2001 Mar; 44(3):305-8. PubMed ID: 11317660 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of subcutaneously administered U40 and U100 formulations of regular human insulin. Heinemann L; Chantelau EA; Starke AA Diabete Metab; 1992; 18(1):21-4. PubMed ID: 1563532 [TBL] [Abstract][Full Text] [Related]
29. Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles. Mudaliar S; Mohideen P; Deutsch R; Ciaraldi TP; Armstrong D; Kim B; Sha X; Henry RR Diabetes Care; 2002 Sep; 25(9):1597-602. PubMed ID: 12196433 [TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetic model of human insulin following different routes of administration. Potocka E; Baughman RA; Derendorf H J Clin Pharmacol; 2011 Jul; 51(7):1015-24. PubMed ID: 20940337 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018 [TBL] [Abstract][Full Text] [Related]
32. AIR insulin capsules of different dose strengths may be combined to yield equivalent pharmacokinetics and glucodynamics. de la Peña A; Seger M; Rave K; Heinemann L; Silverman B; Muchmore DB Diabetes Technol Ther; 2009 Sep; 11 Suppl 2():S75-80. PubMed ID: 19772452 [TBL] [Abstract][Full Text] [Related]
33. The pharmacodynamics and activity of intranasally administered insulin in healthy male volunteers. Jacobs MA; Schreuder RH; Jap-A-Joe K; Nauta JJ; Andersen PM; Heine RJ Diabetes; 1993 Nov; 42(11):1649-55. PubMed ID: 8405708 [TBL] [Abstract][Full Text] [Related]
34. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. Rave K; de la Peña A; Tibaldi FS; Zhang L; Silverman B; Hausmann M; Heinemann L; Muchmore DB Diabetes Care; 2007 Jul; 30(7):1777-82. PubMed ID: 17456839 [TBL] [Abstract][Full Text] [Related]
35. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069 [TBL] [Abstract][Full Text] [Related]
36. Action profiles of fast onset insulin analogues. Heinemann L; Starke AA; Heding L; Jensen I; Berger M Diabetologia; 1990 Jun; 33(6):384-6. PubMed ID: 2199281 [TBL] [Abstract][Full Text] [Related]
37. PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. Heise T; Brugger A; Cook C; Eckers U; Hutchcraft A; Nosek L; Rave K; Troeger J; Valaitis P; White S; Heinemann L Diabetes Obes Metab; 2009 May; 11(5):455-9. PubMed ID: 19236443 [TBL] [Abstract][Full Text] [Related]
38. Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physico-chemical properties of insulin and physiological factors. Hildebrandt P Dan Med Bull; 1991 Aug; 38(4):337-46. PubMed ID: 1914533 [TBL] [Abstract][Full Text] [Related]
39. Acute effects of intraperitoneal versus subcutaneous insulin delivery on glucose homeostasis in patients with NIDDM. Veterans Affairs Implantable Insulin Pump Study Group. Kelley DE; Henry RR; Edelman SV Diabetes Care; 1996 Nov; 19(11):1237-42. PubMed ID: 8908387 [TBL] [Abstract][Full Text] [Related]